Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers

Plain-language summary

This study aims to research therapeutic antibodies against prion diseases by collecting blood samples from relatives of people with genetic prion diseases. It enrolled relatives of patients with genetic prion disease who gave informed consent. It was conducted as a study without a phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

University of Zurich

Intervention

blood draw

Start date

9/1/2015

Estimated completion

3/1/2019

Countries

United States, Austria, Germany, Israel, Italy, Slovakia, Switzerland

Related genes

Locations

• San Francisco, United States
• Graz, Austria
• Göttingen, Germany
• Pardés H̱anna Karkur, Israel
• Milan, Italy
• Bratislava, Slovakia
• Zurich, Switzerland

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Relatives of patients of genetic Prion diseases
* Obtained informed consent

Exclusion Criteria:

* No informed consent